# Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

> **NCT05269628** · PHASE2 · RECRUITING · sponsor: **Tiffany J. Braley, MD, MS** · enrollment: 166 (estimated)

## Conditions studied

- Multiple Sclerosis
- Sleep
- Pain

## Interventions

- **DRUG:** Cannabidiol (CBD)
- **DRUG:** Tetrahydrocannabinol (THC)
- **DRUG:** Placebo CBD
- **DRUG:** Placebo THC

## Key facts

- **NCT ID:** NCT05269628
- **Lead sponsor:** Tiffany J. Braley, MD, MS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-25
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269628, "Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05269628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*